PMID- 35380017
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1738-6756 (Print)
IS  - 2092-9900 (Electronic)
IS  - 1738-6756 (Linking)
VI  - 25
IP  - 3
DP  - 2022 Jun
TI  - Intravenous Immunoglobulin to Suppress Progression in a Patient With Advanced 
      Breast Cancer.
PG  - 253-258
LID - 10.4048/jbc.2022.25.e8 [doi]
AB  - Intravenous immunoglobulin (IVIG) is used to treat various diseases and has 
      anticancer effects that suppress metastases in animal models of sarcoma and 
      melanoma. However, these effects have been observed in a limited number of 
      clinical cases. We report the case of a patient with metastatic breast cancer in 
      which long-term IVIG treatment stopped disease progression in the absence of 
      salvage chemotherapy. The patient was treated with IVIG for the treatment of 
      immune thrombocytopenia. Surprisingly, the lung and brain metastases were 
      stabilized, and the patient achieved a progression-free interval of 29 months. 
      More cases are needed to investigate and confirm the efficacy of IVIG in solid 
      tumors in the future.
CI  - (c) 2022 Korean Breast Cancer Society.
FAU - Lin, Kai-Liang
AU  - Lin KL
AUID- ORCID: 0000-0002-5730-0659
AD  - Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
FAU - Chao, Ta-Chung
AU  - Chao TC
AUID- ORCID: 0000-0003-1451-1939
AD  - Department of Oncology and Comprehensive Breast Health Center, Taipei Veterans 
      General Hospital, Taipei, Taiwan.
AD  - Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung 
      University, Hsinchu, Taiwan.
FAU - Chen, Ming-Han
AU  - Chen MH
AUID- ORCID: 0000-0001-7822-2613
AD  - Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung 
      University, Hsinchu, Taiwan.
AD  - Division of Allergy- Immunology- Rheumatology, Department of Medicine, Taipei 
      Veterans General Hospital, Taipei, Taiwan. mhchen6@vghtpe.gov.tw.
LA  - eng
GR  - Taiwan Clinical Oncology Research Foundation/Taiwan
PT  - Case Reports
DEP - 20220217
PL  - Korea (South)
TA  - J Breast Cancer
JT  - Journal of breast cancer
JID - 101314183
PMC - PMC9250874
OTO - NOTNLM
OT  - Carcinoma, Ductal, Breast
OT  - Immunoglobulins, Intravenous
OT  - Purpura, Thrombocytopenic, Idiopathic
COIS- The authors declare that they have no competing interests.
EDAT- 2022/04/06 06:00
MHDA- 2022/04/06 06:01
PMCR- 2022/06/01
CRDT- 2022/04/05 05:33
PHST- 2021/11/07 00:00 [received]
PHST- 2022/01/18 00:00 [revised]
PHST- 2022/02/13 00:00 [accepted]
PHST- 2022/04/06 06:00 [pubmed]
PHST- 2022/04/06 06:01 [medline]
PHST- 2022/04/05 05:33 [entrez]
PHST- 2022/06/01 00:00 [pmc-release]
AID - 25.e8 [pii]
AID - 10.4048/jbc.2022.25.e8 [doi]
PST - ppublish
SO  - J Breast Cancer. 2022 Jun;25(3):253-258. doi: 10.4048/jbc.2022.25.e8. Epub 2022 
      Feb 17.